Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial

Køber, Lars; Thomsen, Poul Erik Bloch; Møller, Mogens; Torp‐Pedersen, Christian; Carlsen, Jens; Sandøe, Erik; Egstrup, Kenneth; Agner, E; Videbæk, J; Marchant, Bradley; Camm, A. John

doi:10.1016/s0140-6736(00)03402-4

Cited by 309 publications

(218 citation statements)

References 29 publications

Supporting

Mentioning

203

Contrasting

Unclassified

Order By: Relevance

“…27 In the DIAMOND-MI trial, in which continuous 3-day in-hospital ECG monitoring was used, a TdP rate of 0.94% was reported among patients taking dofetilide. 28 Severe neutropenia was also more frequent in azimilide 100 mg patients than placebo patients.…”

Section: Discussionmentioning

confidence: 99%

Mortality in Patients After a Recent Myocardial Infarction

et al. 2004

View full text Add to dashboard Cite

Background-Depressed left ventricular function (LVF) and low heart rate variability (HRV) identify patients at risk of increased mortality after myocardial infarction (MI). Azimilide, a novel class III antiarrhythmic drug, was investigated for its effects on mortality in patients with depressed LVF after recent MI and in a subpopulation of patients with low HRV. Methods and Results-A total of 3717 post-MI patients with depressed LVF were enrolled in this randomized, placebo-controlled, double-blind study of azimilide 100 mg on all-cause mortality. Placebo patients with low HRV had a significantly higher 1-year mortality than those with high HRV (Ͼ20 U; 15% versus 9.5%, PϽ0.0005) despite nearly identical ejection fractions. No significant differences were observed between the 100-mg azimilide and placebo groups for all-cause mortality in either the "at-risk" patients identified by depressed LVF (12% versus 12%) or the subpopulation of "high-risk" patients identified by low HRV (14% versus 15%) or for total cardiac or arrhythmic mortality. Significantly fewer patients receiving azimilide developed atrial fibrillation than did patients receiving placebo (0.5% versus 1.2%, PϽ0.04). The incidences of torsade de pointes and severe neutropenia (absolute neutrophil count Յ500 cells/L) were slightly higher in the azimilide group than in the placebo group (0.3% versus 0.1% for torsade de pointes and 0.9% versus 0.2% for severe neutropenia). Conclusions-Azimilide

show abstract

Section: Discussionmentioning

confidence: 99%

Mortality in Patients After a Recent Myocardial Infarction

et al. 2004

View full text Add to dashboard Cite

show abstract

“…However, amiodarone therapy is neutral with respect to all-cause mortality and is associated with a 2 and 5 fold increased risk of pulmonary and thyroid toxicity respectively [33]. Dofetilide and azimilide did not demonstrate a mortality benefit either [34][35][36]. In summary, there is little role for prophylactic antiarrhythmic medications for the primary prevention of SCD in patients with HF except amiodarone.…”

Section: Antiarrhythmic Drugsmentioning

confidence: 99%

Management of arrhythmias in heart failure. What a practicing physician should know in the current times

Ramineni¹,

Bheemarasetti²,

Baranchuk³

et al. 2012

Cardiol J

View full text Add to dashboard Cite

show abstract

“…15 The most disturbing data with dronedarone come from the Antiarrhythmic Trial with Dronedarone in Moderate to Severe CHF Evaluating Morbidity Decrease (ANDROMEDA) in which use of the drug significantly increased the mortality rate, compared with placebo, in patients hospitalized with new or worsening heart failure (NYHA class III or IV) and an LVEF of 35% or less. 16 In ANDROMEDA, only about one fourth of the patients were in atrial fibrillation at study entry. The apparent mode of death associated with dronedarone was worsened heart failure, with a higher risk of death in patients with poorer left ventricular function.…”

Section: Dronedarone Clinical Trial Datamentioning

confidence: 99%

Untitled

2010

Pharmacotherapy

View full text Add to dashboard Cite

Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial

Cited by 309 publications

References 29 publications

Mortality in Patients After a Recent Myocardial Infarction

Mortality in Patients After a Recent Myocardial Infarction

Management of arrhythmias in heart failure. What a practicing physician should know in the current times

Untitled

Contact Info

Product

Resources

About